Feline Cardiomyopathy: Phenotype Differentiation and Treatment

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Feline cardiomyopathy is a heterogeneous group of myocardial disorders classified by echocardiographic phenotype: Hypertrophic Cardiomyopathy (HCM), Restrictive Cardiomyopathy (RCM), Dilated Cardiomyopathy (DCM), and a Nonspecific phenotype. HCM is characterized by diastolic dysfunction and concentric hypertrophy, RCM by diastolic dysfunction and endomyocardial fibrosis, and DCM by systolic failure and ventricular dilation.
• Accurate phenotyping is critical as treatment strategies, including positive inotropes, afterload reduction, and antithrombotic therapy, are phenotype-dependent. HCM is the most prevalent, but RCM and DCM are often under-recognized until heart failure or arterial thromboembolism (ATE) occurs.
• Diagnostic differentiation requires excluding secondary causes like systemic hypertension and hyperthyroidism, followed by experienced echocardiographic assessment of wall thickness, chamber dimensions, and Doppler flow patterns. Genetic testing for HCM has limited clinical utility due to high variant prevalence in unaffected cats.
• Treatment goals include controlling congestive signs, reducing thromboembolic risk, and slowing disease progression, with therapy individualized based on clinical stage and echocardiographic findings. Diuretics (e.g., furosemide) are first-line for heart failure, pimobendan is used in DCM and HCM with systolic dysfunction, and atenolol is reserved for specific HCM indications like outflow tract obstruction.
• Complications include congestive heart failure (CHF), arterial thromboembolism (ATE), and sudden cardiac death. Early detection of CHF relies on owner monitoring of resting respiratory rate (above 30 breaths/min), while ATE risk increases with left atrial diameter exceeding 15-16 mm.
• Treatment evidence is often derived from small studies or extrapolation from human medicine, necessitating consultation of current ACVIM consensus statements and formulary references. Referral to a veterinary cardiologist is indicated for ambiguous phenotypes, refractory heart failure, or recurrent ATE.

Feline cardiomyopathy encompasses a heterogeneous group of myocardial disorders that differ in pathophysiology, echocardiographic appearance, clinical progression, and response to therapy. This article provides a diagnostic framework for differentiating the principal phenotypes, hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), dilated cardiomyopathy (DCM), and the nonspecific phenotype, and aligns each with evidence-informed treatment strategies. The intended reader is the practicing veterinarian who encounters cats with murmurs, arrhythmias, or signs of congestive heart failure and needs a structured approach to classification and management.

The clinical stakes of accurate phenotyping are substantial. HCM dominates feline practice, with a reported prevalence of 14.7% in one survey of cardiovascular disease in cats, but the non-HCM cardiomyopathies are frequently under-recognized until a cat presents with heart failure or arterial thromboembolism. Treatment decisions, including the choice of positive inotropes, afterload reduction, and antithrombotic therapy, depend on whether the dominant problem is diastolic dysfunction, systolic failure, or a mixed picture. This article assumes familiarity with echocardiographic technique and cardiovascular pharmacology and focuses on the reasoning that connects phenotype to therapy.

At a Glance

Pathophysiology and Phenotype Classification

The cardiomyopathies are defined by structural and functional myocardial abnormalities in the absence of congenital defects, valvular disease, or systemic conditions sufficient to explain the changes. Classification in cats follows echocardiographic phenotype, and the same heart may evolve from one phenotype to another over time, which complicates both diagnosis and treatment planning.

Hypertrophic Cardiomyopathy

HCM is characterized by increased myocardial mass with concentric hypertrophy that is often asymmetric and primarily affects the left ventricle. The hypertrophy results in diastolic dysfunction, reduced intracavitary internal diameter, and impaired relaxation due to disordered cardiomyocyte alignment and excessive collagen deposition. The feline phenotype closely resembles the human disease, but the time course is compressed, with affected cats progressing to heart failure, thromboembolism, or sudden death over months to years instead of decades.

Genetic studies in cats have identified variants in two sarcomeric genes, MYBPC3 and MYH7, that are also associated with human disease. However, the high prevalence of these variants in non-affected cats complicates the interpretation of pathogenicity in heterozygotes, and genetic testing currently has limited clinical utility for diagnosis or prognosis. The diagnosis therefore rests on echocardiography, with an end-diastolic left ventricular wall thickness of 6 mm or greater defining the HCM phenotype in cats without concurrent systemic disease.

Restrictive Cardiomyopathy

RCM is characterized by diastolic dysfunction due to myocardial fibrosis that produces a restrictive transmitral flow pattern on Doppler echocardiography, usually with marked left or biatrial enlargement. Systolic function is typically preserved in the early stages, and the ventricular walls are not thickened. The diagnosis is often made only when a cat presents with heart failure or systemic thromboembolism, because subclinical RCM rarely produces auscultatory abnormalities that prompt echocardiography.

Dilated Cardiomyopathy

DCM is defined by decreased myocardial contractility with ventricular dilation and is rare in cats. When it occurs, it is seldom attributable to taurine deficiency in contemporary practice, although taurine deficiency remains a historical cause that should still be excluded. A juvenile idiopathic form has been reported in a 10-week-old Oriental shorthair kitten with biventricular dilation, reduced contractility, and congestive failure, with postmortem findings of interstitial and endocardial fibrosis. This case illustrates that DCM can present in young cats without an identifiable underlying cause, and that the echocardiographic phenotype may be accompanied by significant secondary fibrosis.

Nonspecific Phenotype

The nonspecific phenotype, formerly termed unclassified cardiomyopathy, is a catch-all category for hearts with myocardial changes that either do not meet the criteria for any single cardiomyopathy or meet criteria for more than one type. These cats are common in referral practice and present a particular therapeutic challenge because the dominant pathophysiology may shift as the disease progresses. Serial echocardiography is often necessary to determine whether diastolic or systolic dysfunction predominates at any given time.

Diagnostic Reasoning and Phenotype Differentiation

The first step in phenotype assignment is to exclude systemic diseases that can produce secondary myocardial changes. Systemic hypertension and hyperthyroidism can cause left ventricular hypertrophy that mimics HCM, and cats with these conditions should be excluded from a primary HCM diagnosis. The diagnostic evaluation therefore includes blood pressure measurement, serum total thyroxine concentration, and a thorough physical examination before echocardiography is interpreted.

Echocardiography should be performed by an operator experienced in feline cardiac ultrasound, using a probe appropriate for the cat's size. The examination must include two-dimensional assessment of wall thickness and chamber dimensions, M-mode measurements when image quality permits, and Doppler evaluation of transmitral flow, pulmonary venous flow, and left atrial size. The restrictive transmitral flow pattern characteriztic of RCM is distinguished from the relaxation abnormalities seen in early HCM by the presence of marked atrial enlargement and a short deceleration time. DCM is distinguished from the other phenotypes by the combination of ventricular dilation and reduced fractional shortening, with no identifiable congenital defect.

Therapeutic Principles Across Phenotypes

Treatment goals differ by phenotype but share common elements: control of congestive signs, reduction of thromboembolic risk, and slowing of disease progression where possible. Current evidence does not support a single universal protocol, and therapy must be individualized based on the cat's clinical stage, echocardiographic findings, and tolerance of medications. The ACVIM consensus statements provide phenotype-specific guidance that should be consulted alongside current formulary references for dosing and monitoring recommendations.

Treatment Planning by Phenotype

Hypertrophic Cardiomyopathy: Stage-Based Therapy

Treatment of feline HCM follows the stage of disease instead of the echocardiographic phenotype alone. Cats in stage B1, defined as subclinical disease without substantial atrial enlargement, typically receive no medication. Regular rechecks every 6 to 12 months detect progression to stage B2, where left atrial enlargement is present and the risk of arterial thromboembolism and congestive heart failure rises. The decision to initiate antiplatelet therapy in stage B2 rests on the owner's ability to administer daily medication, the cat's temperament, and the measured left atrial diameter. Clopidogrel is the preferred antiplatelet agent in most published recommendations, though the evidence base for its superiority over aspirin in cats remains limited to small comparative studies.

Beta-blockade with atenolol is reserved for specific indications: dynamic left ventricular outflow tract obstruction, persistent sinus tachycardia, or ventricular arrhythmias. The presence of outflow tract obstruction is confirmed by Doppler interrogation of the left ventricular outflow tract, and the decision to treat is guided by the measured gradient and the presence of concurrent mitral regurgitation. Atenolol slows heart rate, prolongs diastole, and may reduce myocardial oxygen demand, but it does not alter the underlying myocardial pathology. Cats with HCM and congestive heart failure require loop diuretic therapy, most commonly furosemide, titrated to the lowest effective dose that maintains euvolemia. Pimobendan is used in cats with HCM and heart failure despite initial diuretic therapy, although its role in purely diastolic disease remains debated. The ACVIM consensus statements provide the most current framework for staging and treatment decisions, and the clinical-diagnostic and therapeutic advances in feline hypertrophic cardiomyopathy summarize the evidence supporting each drug class.

Restrictive Cardiomyopathy: Managing Diastolic Failure

RCM in cats is characterized by severe diastolic dysfunction with restrictive transmitral flow and marked atrial enlargement, often with minimal ventricular wall thickening. Treatment targets the consequences of elevated filling pressures instead of the myocardial fibrosis itself. Furosemide is the mainstay for congestive signs, and the dose is adjusted to maintain a respiratory rate below 30 breaths per minute at rest. Pimobendan may be considered in RCM despite the absence of systolic dysfunction, because improved lusitropy and reduced filling pressures can benefit some cats, but the evidence is extrapolated from HCM studies and clinical experience. Antithrombotic prophylaxis is indicated in cats with marked atrial enlargement, as the thromboembolic risk in RCM is at least as high as in HCM. The feline cardiomyopathies other than HCM review notes that RCM is rarely diagnosed before heart failure or thromboembolism develops, so treatment is often initiated at a crisis point instead of during a subclinical window.

Dilated Cardiomyopathy: Identifying Reversible Causes

DCM is now uncommon in cats, largely because taurine deficiency has been corrected in commercial diets. When DCM is diagnosed, the clinician must still measure whole blood taurine, because taurine-responsive DCM has not disappeared entirely. Taurine supplementation is inexpensive and safe, and it should be started immediately while awaiting results. Pimobendan is the primary positive inotrope for feline DCM, and furosemide is added when congestive signs are present. The prognosis for taurine-responsive DCM is favourable if supplementation begins before refractory heart failure develops. The dilated cardiomyopathy phenotype in a 10-week-old Oriental shorthair kitten illustrates that juvenile idiopathic DCM occurs without an identifiable cause, and in such cases the response to therapy is poor. Breed predisposition has been suggested in some reports, but the evidence is insufficient to justify breed-specific screening programs.

Nonspecific Phenotype and Arrhythmogenic Right Ventricular Cardiomyopathy

The nonspecific phenotype, previously termed unclassified cardiomyopathy, includes hearts that do not meet the criteria for any single cardiomyopathy or that meet criteria for more than one. Treatment follows the dominant clinical problem. If heart failure predominates, diuretic therapy is the priority. If arrhythmias are the primary concern, Holter monitoring or ambulatory event recording guides antiarrhythmic selection. ARVC is characterized by right ventricular enlargement and arrhythmias, and treatment focuses on arrhythmia suppression and heart failure management when present. The feline cardiomyopathies other than HCM review emphasizes that these phenotypes are rarely identified before clinical decompensation, so the treatment plan is often reactive instead of preventive.

Monitoring Parameters and Recheck Intervals

The recheck interval is shortened when clinical signs change, when a drug dose is adjusted, or when the owner reports an elevated resting respiratory rate. Home monitoring of respiratory rate is the single most useful parameter for detecting early congestive heart failure, and it should be taught to every owner of a cat with cardiomyopathy. Blood pressure measurement is mandatory in older cats because systemic hypertension can cause or worsen left ventricular hypertrophy, and the prevalence of cardiomyopathy in non-purebred cats study excluded hypertensive cats from the HCM diagnosis for this reason.

Drug Selection and Dose Adjustment

Drug selection in feline cardiomyopathy is guided by the phenotype, the presence of congestive heart failure, and the cat's tolerance of oral medication. Furosemide is the first-line diuretic for all phenotypes when pulmonary edema or pleural effusion is present. The starting dose is adjusted to effect, and the goal is the lowest dose that keeps the cat free of congestive signs without causing azotaemia or hypokalemia. Spironolactone is added in cats that require high furosemide doses or that develop hypokalemia, though its use in cats is supported by limited data. Pimobendan is used in DCM, in HCM with systolic dysfunction, and in some cats with RCM and refractory heart failure. Atenolol is reserved for HCM with outflow tract obstruction or significant arrhythmia. Diltiazem is an alternative rate-control agent but is less commonly used because of its negative inotropic effect.

Current formulary and label references must be consulted before prescribing, because doses vary with formulation and the evidence base for each drug in cats is incomplete. The MSD Veterinary Manual provides species-specific pharmacology summaries, and the AVMA practice resources offer guidance on professional standards of care. No drug currently available reverses the underlying myocardial pathology in any feline cardiomyopathy, and treatment goals are therefore clinical stability, quality of life, and prevention of thromboembolism.

When to Refer and When to Stop

Referral to a veterinary cardiologist is indicated when the phenotype is ambiguous on echocardiography, when the cat fails to stabilize on standard therapy, or when advanced imaging such as cardiac MRI is considered. General practitioners can manage most stable cases with serial echocardiography and blood pressure measurement, but the threshold for referral should be low in cats with recurrent heart failure, suspected pulmonary hypertension, or complex arrhythmias. Euthanasia is a legitimate outcome when congestive heart failure becomes refractory to escalating diuretic therapy, when thromboembolism causes severe pain and paralysis, or when the cat's quality of life declines despite optimal medical management. The decision is made collaboratively with the owner, and the clinician should provide honest prognostic information based on the phenotype and the response to therapy.

Recognized Complications and Early Detection

The dominant complications across feline cardiomyopathy phenotypes are congestive heart failure, arterial thromboembolism (ATE), and sudden cardiac death. Congestive heart failure is detected earliest through serial body weight measurement, respiratory rate monitoring at rest, and thoracic auscultation for crackles or a gallop rhythm. Owners should be trained to count resting respiratory rate during sleep, a sustained rate above 30 breaths per minute precedes radiographic pulmonary edema in most cats. Arterial thromboembolism presents as acute pelvic limb paresis with absent femoral pulses, cold extremities, and firm gastrocnemius muscles. The risk of ATE rises with left atrial diameter exceeding 15 to 16 mm on two-dimensional echocardiography, spontaneous echo contrast, or a documented thrombus. Sudden cardiac death remains unpredictable, although cats with syncope, complex ventricular arrhythmias, or severe left atrial enlargement carry higher risk.

Pleural effusion complicates restrictive and nonspecific phenotypes more often than hypertrophic cardiomyopathy. Cats with right-sided or biventricular failure present with tachypnoea, quiet lung sounds dorsally, and muffled heart sounds. Thoracic ultrasound identifies the effusion rapidly, and therapeutic thoracocentesis provides both diagnosis and relief. Systemic hypertension and hyperthyroidism can induce or exacerbate left ventricular hypertrophy and must be excluded before attributing the phenotype to primary cardiomyopathy. The New Zealand colony study excluded cats with these comorbidities before confirming an HCM phenotype, and the same discipline applies in clinical practice.

Common Diagnostic and Therapeutic Errors

Less experienced clinicians frequently misclassify phenotype when image quality is suboptimal or when concurrent disease alters ventricular geometry. A cat with severe dehydration and tachycardia may show transiently reduced chamber dimensions that mimic hypertrophy. Corrective action is to repeat echocardiography after fluid resuscitation and heart rate control. Another common error is diagnosing HCM from a single thickened wall segment without integrating diastolic function, left atrial size, and Doppler findings. The restrictive phenotype requires a restrictive transmitral filling pattern, also atrial enlargement. The review of non-HCM cardiomyopathies emphasizes that echocardiography is the definitive confirmatory test and that the nonspecific phenotype groups hearts that meet criteria for no single category or for several at once.

Treatment errors center on dose escalation without recheck imaging, using furosemide alone for heart failure without addressing the underlying phenotype, and failing to taper or stop antiplatelet therapy when contraindications develop. Beta-blockade initiated during acute decompensation can precipitate worsening failure. Calcium channel blockade in a cat with dynamic outflow obstruction may increase the gradient. The corrective framework is stage-based therapy: stabilize first, then phenotype-specific long-term management, then recheck and adjust.

Evidence Limitations and Contested Areas

The evidence base for feline cardiomyopathy treatment is thinner than for human HCM. Most drug recommendations derive from small studies, expert opinion, or extrapolation from human medicine. The 2025 literature review on feline HCM notes that certain aspects of the disease remain insufficiently understood and that ongoing studies are essential to refine diagnostic strategies and explore novel treatment options. Genetic testing is particularly contested. The genetics review reports that the high prevalence of the identified MYBPC3 and MYH7 variants in non-affected cats hinders assuming pathogenicity in heterozygotes. A positive genetic test does not confirm disease, and a negative test does not exclude it. Breeders and owners should receive this context before testing.

The role of taurine supplementation in DCM remains debated. Deficiency is now rare in cats fed commercial diets, but supplementation is inexpensive and harmless, so many clinicians add it while investigating other causes. The case report of juvenile idiopathic DCM in an Oriental shorthair kitten illustrates that some DCM cases have no identifiable cause even after full postmortem evaluation. Expert opinion still differs on the threshold for starting antiplatelet therapy, the target heart rate for beta-blockade, and whether pimobendan should be used in cats with HCM and systolic dysfunction. These decisions should be individualised and documented.

Referral, Consultation, and Reporting

Referral to a veterinary cardiologist is warranted when the phenotype cannot be classified confidently, when the cat is in congestive heart failure that does not stabilize within 24 to 48 hours, when ATE recurs despite therapy, or when interventional procedures such as pericardiocentesis or pacemaker placement are considered. A board-certified cardiologist should also guide management of breeding animals, because phenotype classification and genetic counseling have direct implications for breeding programs. The ACVIM consensus statements provide the framework for diagnosis and management that referral clinicians apply.

Laboratory involvement is indicated for suspected hyperthyroidism, hypertension, or taurine deficiency. Thyroid testing should precede final phenotype assignment in any cat over eight years with newly detected hypertrophy. Blood pressure measurement is mandatory before starting cardiovascular drugs, because undetected hypertension changes both diagnosis and therapy.

Regulatory reporting is rarely required for feline cardiomyopathy. It becomes relevant only when a cat is involved in clinical trials, when a drug is used under a cascade or extra-label provision that requires record keeping, or when a suspected adverse drug reaction occurs. The AVMA practice resources and the WOAH terrestrial animal health standards describe professional obligations that vary by jurisdiction. Clinicians should know their local requirements for adverse event reporting and controlled drug documentation. The MSD Veterinary Manual provides baseline pharmacology and dosing references that should be checked against current product labeling before prescribing.

Frequently Asked Questions

How Should I Manage a Cat with Suspected Cardiomyopathy When Echocardiography Is Unavailable?

When echocardiography is not accessible, phenotype differentiation relies on signalment, physical examination, thoracic radiography, and blood pressure measurement. Radiographic evidence of left atrial enlargement with a normal or minimally enlarged ventricular silhouette supports a diastolic phenotype such as hypertrophic or restrictive cardiomyopathy. A globoid cardiac silhouette with pulmonary venous distension raises suspicion for dilated cardiomyopathy. N-terminal pro-B-type natriuretic peptide measurement can support a cardiac diagnosis but does not distinguish phenotypes. Blood pressure measurement and thyroid hormone testing are mandatory to exclude secondary myocardial changes. Empirical therapy should target congestive heart failure with diuretics and, when indicated, pimobendan, while arranging referral for definitive imaging. Document the diagnostic limitation clearly in the medical record and revisit the diagnosis if the cat fails to respond as expected.

What Is the Role of Genetic Testing in Clinical Feline Cardiomyopathy Cases?

Genetic testing has a limited clinical role in most feline cardiomyopathy cases. Variants in MYBPC3 and MYH7 have been identified in cats, but the high prevalence of these variants in non-affected cats complicates interpretation of pathogenicity in heterozygotes, as described in genetics of feline hypertrophic cardiomyopathy. Testing is most useful for breeding decisions in breeds with known variant associations, particularly Maine Coon and Ragdoll cats. A negative result does not exclude cardiomyopathy, and a positive result does not confirm that an individual cat will develop disease. Echocardiographic screening remains the reference standard for diagnosis. Counsel owners that genetic testing complements, but does not replace, regular cardiac evaluation.

How Do I Approach Cardiomyopathy in a Kitten or Juvenile Cat?

Cardiomyopathy in kittens is uncommon but occurs. A dilated cardiomyopathy phenotype has been reported in a 10-week-old Oriental shorthair kitten with stunted growth, dyspnea, and biventricular failure, where postmortem examination confirmed the phenotype without an identifiable underlying cause. In juvenile cats, exclude congenital heart defects before attributing myocardial changes to a primary cardiomyopathy. Nutritional taurine deficiency should be considered historically, though it is now rare with commercial diets. Infectious, inflammatory, and toxic causes warrant investigation. Prognosis is often guarded, and the evidence base for treatment in this age group is limited. Refer early to a cardiologist when a kitten presents with suspected myocardial disease, and discuss the diagnostic uncertainty and prognostic limitations with the owner.

What Monitoring Is Required for Cats on Long-Term Cardiac Medication?

Recheck intervals depend on disease stage and drug profile. Cats in stable subclinical disease typically require examination and echocardiography every 6 to 12 months. Cats with congestive heart failure require more frequent reassessment, often at 1 to 4 week intervals initially, then every 3 to 6 months once stable. Each recheck should include body weight, heart rate, respiratory rate at rest, auscultation, and blood pressure measurement. Renal parameters and electrolytes should be monitored in cats receiving diuretics or ACE inhibitors, particularly after dose changes. Owners should be taught to track resting respiratory rate at home, as a sustained increase often precedes overt congestive failure. Adjust therapy based on trends instead of single measurements, and document all dose changes and the rationale in the medical record.

How Do I Discuss Prognosis and Treatment Costs with an Owner Realistically?

Begin by confirming the phenotype, as prognosis differs substantially between hypertrophic, restrictive, and dilated cardiomyopathy. Explain that treatment aims to control clinical signs and slow progression instead of cure the disease, consistent with clinical-diagnostic and therapeutic advances in feline hypertrophic cardiomyopathy. Provide a written estimate covering initial stabilization, monitoring, and anticipated long-term medication costs. Discuss the possibility of acute decompensation, including arterial thromboembolism, and the owner's wishes regarding emergency intervention. Offer staged treatment options where financial constraints exist, prioritizing therapies with the strongest evidence. Document the discussion, including the owner's decisions, in the medical record. Revisit the conversation at each recheck, as the cat's status and the owner's circumstances may change.

When Should I Recommend Euthanasia for a Cat with Cardiomyopathy?

Euthanasia is appropriate when congestive heart failure becomes refractory to maximal medical therapy, when respiratory distress cannot be palliated, when thromboembolism causes severe pain or irreversible limb dysfunction, or when the cat's quality of life deteriorates despite optimal management. Use a structured quality-of-life assessment covering appetite, mobility, breathing effort, grooming, and social interaction. If the owner reports more bad days than good days over several weeks, or if the cat requires hospitalization more than twice in a short period, discuss euthanasia openly. The decision is ultimately the owner's, but the veterinarian should provide a clear recommendation based on objective findings instead of leaving the owner to decide alone. Document the discussion and the factors considered in the medical record.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Genetics of feline hypertrophic cardiomyopathy.. 2020.
• The Feline Cardiomyopathies: 3. Cardiomyopathies other than HCM.. 2021.
• Clinical-Diagnostic and Therapeutic Advances in Feline Hypertrophic Cardiomyopathy.. 2025.
• Prevalence of cardiomyopathy and cardiac mortality in a colony of non-purebred cats in New Zealand.. 2025.
• Dilated cardiomyopathy phenotype in a 10-week-old Oriental shorthair kitten.. 2025.
• Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes.. 1995.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Feline Epilepsy: Diagnostic Approach and Treatment
• Feline Hypertrophic Cardiomyopathy: Screening and Management
• Feline Hyperthyroidism: Treatment Selection and Monitoring Plan
• Feline Systemic Hypertension: Screening and Management
• Canine Hyperadrenocorticism: Treatment Options and Monitoring

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.